China will further regulate stem cell clinical experiments to protect the interests of providers and testees, according to draft rules by medical watchdogs. The Ministry of Health (MOH) and the State Food and Drug Administration (SFDA) jointly publicized the draft rules on Thursday to solicit public opinions. All clinical experiments on stem cells are subject to ethical review, said the the regulations. Researchers must submit relevant materials surrounding stem cell products, selection criteria and detailed consent forms of providers and testees, safety evaluation reports, research plans, and resumes of main participating researchers to the ethical board for review. Only top-level hospitals certified by the SFDA as eligible for carrying out drug clinical tests can apply to be stem cell clinical experiment bases. Also according to the rules, during the first three phases of stem cell clinical experiments, testees should not be charged. Medical institutions that violate the rules will lose their qualification and face penalties.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor